Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...1213141516171819202122...401402»
  • ||||||||||  Niagen (nicotinamide riboside) / ChromaDex
    Trial completion date, Trial primary completion date:  NR-VET: Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans (clinicaltrials.gov) -  Nov 8, 2024   
    P=N/A,  N=144, Recruiting, 
    This emphasizes the need to focus on patient-specific factors in managing partial nephrectomy for small renal masses. Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
  • ||||||||||  Journal:  Musculoskeletal Failure. (Pubmed Central) -  Nov 7, 2024   
    Awareness of the relationship between lifestyle behaviors, systemic chronic inflammation and the development and progression of these 3 common conditions is a key step in prevention, early detection and are essential for addressing the complex interplay of these musculoskeletal disorders. As the global population ages, understanding and effectively preventing and managing osteoarthritis, osteoporosis, and sarcopenia become paramount for promoting healthy aging and mitigating the societal and economic burden associated with these conditions.
  • ||||||||||  Journal:  Educational attainment, brain cortical structure, and sarcopenia: a Mendelian randomization study. (Pubmed Central) -  Nov 7, 2024   
    The study will have revealed the protective causal effect of EA on sarcopenia, which provides a reference for the prevention of sarcopenia at the public health level. We also will have found EA could affect the brain cortical structure, and the brain cortical structure could mediate the protective effect of EA against sarcopenia risk.
  • ||||||||||  Review, Journal:  Late-onset primary muscle diseases mimicking sarcopenia. (Pubmed Central) -  Nov 6, 2024   
    This review outlines the evolution of diagnostic criteria and diagnostic items for sarcopenia, late-onset primary myopathies that should be differentiated from sarcopenia, common pathomechanisms, and diagnostic algorithms to properly differentiate primary myopathies. Geriatr Gerontol Int 2024;
  • ||||||||||  Journal:  Reply to the comments of Saleh et (Pubmed Central) -  Nov 6, 2024   
    Screening for myosteatosis with HUAC using the CT before surgery may help clinicians identify high-risk perioperative patients early. No abstract available
  • ||||||||||  Biomarker, Journal:  C-Reactive Protein Level as a Novel Serum Biomarker in Sarcopenia. (Pubmed Central) -  Nov 6, 2024   
    MR analysis provided further evidence of a significant detrimental link between genetically predicted CRP levels and essential sarcopenia characteristics, with consistent results across various statistical models. Our study uncovered strong evidence supporting a noteworthy inverse association and causality between CRP concentrations and sarcopenia, indicating that CRP has the potential to serve as a biomarker for sarcopenia.
  • ||||||||||  Retrospective data, Review, Journal:  Effects of muscle strength exercise on muscle mass and muscle strength in patients with stroke: a systematic review and meta-analysis. (Pubmed Central) -  Nov 6, 2024   
    The study also compared the effects based on repetition maximum (RM) settings, revealing that strength increased significantly regardless of whether RM was used, with studies showing medium effects (with RM: SMD, 0.52; 95% CI, 0.4-0.64; I 2 =0%; P<0.05; without RM: SMD, 0.65; 95% CI, 0.4-0.91; I 2 =72%; P<0.05). The study concludes that strength exercises are beneficial for improving muscle strength in chronic stroke patients, but the use of RM to set exercise intensity is not strictly necessary.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
    The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2830;    
    Patients received 7+3 (43%), vyxeos (9%), 7+3+ targeted agent (5%), HMA + venetoclax (30%), HMA alone (6%) or other (6%) as frontline therapy...Therefore, the WLGS could be a potential tool to assess for cachexia and improve risk stratification in AML, especially when considering a patient for transplant or treatment for more adverse disease. Future studies are needed to determine if the incorporation of cachexia-based treatment, specifically for higher risk disease, could potentially improve treatment tolerance and survival.
  • ||||||||||  Journal:  Higher protein intake may benefit in patients with prolonged mechanical ventilation. (Pubmed Central) -  Nov 5, 2024   
    Weak positive correlations were found between average protein intake with PF ratio (r?=?0.1576, p?=?0.0227) and PaO2 (r?=?0.13359, p?=?0.0497). Daily protein intake had positively correlated with PF ratio and had independently benefit for weaning in patients with PMV.
  • ||||||||||  cisplatin / Generic mfg.
    Journal, HEOR:  The impact of nutritional intervention on quality of life and outcomes in patients with head and neck cancers undergoing chemoradiation. (Pubmed Central) -  Nov 5, 2024   
    Despite a rapid deterioration of body composition during treatment, nutritional support helped patients to maintain (or in some cases improve) anthropometric parameters from the end of chemoradiotherapy to the following 3 months. Low prealbumin and albumin pre-treatment led to higher risk of toxicities with consequent reduction of cisplatin dose intensity, whereas weight at the end of the treatment seems to be an interesting predicting factor for disease free and overall survival (p=0.007; p=0.015).
  • ||||||||||  Review, Journal:  New horizons in hospital-associated deconditioning: a global condition of body and mind. (Pubmed Central) -  Nov 5, 2024   
    Whilst deconditioning may be reversible with early intervention strategies, the long-term effects can be devastating. In this article, we summarise the most recent research on this topic including new promising interventions and describe our recommendations for implementation of tools such as the Frailty Care Bundle.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  Nutrition and Clinical Outcomes in IBD (clinicaltrials.gov) -  Nov 5, 2024   
    P=N/A,  N=300, Not yet recruiting, 
    In this article, we summarise the most recent research on this topic including new promising interventions and describe our recommendations for implementation of tools such as the Frailty Care Bundle. Trial completion date: May 2028 --> Dec 2028 | Initiation date: Sep 2024 --> Sep 2025 | Trial primary completion date: Dec 2027 --> Dec 2028
  • ||||||||||  Trial initiation date:  STaR: Strength Training and Resveratrol (clinicaltrials.gov) -  Nov 4, 2024   
    P=N/A,  N=36, Not yet recruiting, 
    Trial completion date: May 2028 --> Dec 2028 | Initiation date: Sep 2024 --> Sep 2025 | Trial primary completion date: Dec 2027 --> Dec 2028 Initiation date: Oct 2024 --> Feb 2025
  • ||||||||||  Journal:  Sarcopenia in the era of precision health: Towards personalized interventions for healthy longevity. (Pubmed Central) -  Nov 4, 2024   
    Future directions include refining Asian-specific diagnostic criteria, conducting large-scale epidemiological studies across multiple Asian countries, developing culturally appropriate interventions, integrating sarcopenia management into chronic disease care, and advancing pharmaceutical research with a focus on Asian populations. In conclusion, sarcopenia emerges as a critical nexus in the aging process, intricately linked with multiple organ systems and chronic conditions, underscoring the imperative for its recognition as a cornerstone in person-centered care and the holistic management of age-related health challenges.
  • ||||||||||  Review, Journal:  Molecular mechanism of skeletal muscle loss and its prevention by natural resources. (Pubmed Central) -  Nov 4, 2024   
    In addition, we summarized accumulated studies of natural resources investigating their roles in ameliorating the loss of skeletal muscle mass and demonstrating the underlying mechanisms in vitro and in vivo. In conclusion, following the studies of natural resources exerting the preventive activity in muscle mass loss, the signaling-based approaches may accelerate the development of functional foods for sarcopenia prevention.
  • ||||||||||  Review, Journal:  Tailoring meat products for the elderly: A comprehensive review. (Pubmed Central) -  Nov 3, 2024   
    This review also highlights the ongoing efforts in developing meat-based products that span a spectrum of consistencies, ranging from solid to liquid forms, to accommodate the diverse needs of elderly consumers. Despite these advancements, the review found a discrepancy between the pace of meat product development for the elderly and the rapid advancements in kitchen-level technologies and suggests that further research is needed to bridge this gap and align product innovation with emerging technological trends.